Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market

Sangamo Therapeutics (NASDAQ:SGMO) announced a Nasdaq delisting and transition to the OTCQB Venture Market effective May 5, 2026, after failing to comply with the exchange’s minimum bid price requirement. The move is significant for investors as it changes where the stock trades and may affect liquidity and visibility.

Key Investor Takeaways

• Nasdaq delisting will take effect May 5, with trading moving to OTCQB under the same ticker.

• SGMO plans to appeal the delisting decision, but trading suspension will still proceed.

• The company stated no expected material impact to business operations.

• Sangamo is pursuing capital raises and potential business development deals.

• OTC trading may impact liquidity and institutional participation for SGMO shares.

Press Release Overview

Sangamo said its common stock will be delisted from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.

Trading on Nasdaq is expected to be suspended at the open on May 5, 2026. The company intends to request a hearing to appeal the decision, although this will not delay the suspension.

The stock has been approved to trade on the OTCQB Venture Market, operated by OTC Markets Group, and will continue trading under the ticker SGMO starting May 5.

Sangamo said the transition is not expected to materially affect its operations. The company also noted it is exploring capital-raising opportunities and evaluating strategic options.

Why This Matters for Investors

The Nasdaq delisting could have implications for trading dynamics. Stocks moving to OTC markets often experience reduced liquidity, wider bid-ask spreads, and lower visibility among institutional investors.

While the company stated operations remain unaffected, the shift in listing venue may influence investor perception and access to capital.

At the same time, Sangamo’s ongoing efforts to secure financing and pursue business development deals may become more critical following the delisting.

What to Watch For Next

• Outcome of Sangamo’s appeal process with Nasdaq

• Execution of potential business development transactions

• Any capital raises or financing announcements

• Trading behavior and liquidity after the move to OTCQB

Conclusion

Sangamo’s Nasdaq delisting marks a key structural shift for the stock, even as the company continues to pursue strategic and financing initiatives. For investors, the focus now turns to execution and how the OTC transition impacts trading and sentiment.

Sangamo Therapeutics stock price